• darkblurbg

    Developing precision therapies

    for type 1 diabetes

  • darkblurbg

    Intralymphatic immunotherapy

    with Diamyd®

Available positions at Diamyd Medical

We welcome candidates with relevant experience to join our entrepreneurial and collaborative team.

The scientific rational and evidence supporting our therapeutic diabetes vaccine Diamyd® was further strengthened the past quarter with three articles published in peer-reviewed scientific journals.

Ulf Hannelius
President and CEO, Diamyd Medical AB
CEO Comments, Quarterly Report 3 21/22

Company Presentation

 June 22, 2022


 Dates for financial information and other events
October 5, 2022
Year-End Report
Year-End Report 2021/2022
October 24 − October 26, 2022
BIO-Europe Leipzig, Germany.
November 10, 2022
Annual Report
Annual Report 2021/2022
December 1, 2022
Annual General Meeting
Annual General Meeting 2021/2022
January 25, 2023
Quarterly Report I
Quarterly Report 1 2022/2023
April 5, 2023
Quarterly Report II
Quarterly Report 2 2022/2023
June 28, 2023
Quarterly Report III
Quarterly Report 3 2022/2023
October 11, 2023
Year-end report
Year-end report 2022/2023


Diamyd Medical develops therapies for type 1 diabetes
The share is listed on Nasdaq First North Growth Market (ticker: DMYD B)

Read More

Order GAD for preclinical research